STAAR SURGICAL CO
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $STAA in the last 30 days.
See all $STAA insider activity →STAAR Surgical (STAA) announced a $50M share repurchase program over 12 months, funded by free cash flow and cash on hand. The company has 50.1M shares outstanding as of August 2026. Analysts project revenues of $400M and earnings of $36.5M by 2029, assuming 11.3% yearly revenue growth. The buyback plan indicates management's focus on capital allocation amid demand and cost pressures in key markets like China.
STAAR Surgical appointed David Bailey, former CEO, as Chief Commercial Officer to lead EVO ICL business. Bailey previously grew international revenue to 74% and ICL revenue to $32 million. He will focus on expanding in Asia, South America, and Africa.
STAAR Surgical (NASDAQ:STAA) shares rose 2% after-hours after announcing a $50M share repurchase program. The medical device company plans to buy back shares over the next year, subject to market conditions. The authorization reflects confidence in its business and financial strength, according to the company.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning STAA (STAAR SURGICAL CO). Coverage has skewed bullish: 4 bullish, 2 neutral, and 0 bearish.
Recent STAA coverage spans corporate actions, financial news and earnings.
The modest buyback may provide slight upward pressure on the stock as it signals confidence, but impact is limited given the small size relative to market cap.
Executive appointment may improve commercial execution for EVO ICL, but limited immediate price impact.
Buyback authorization signals confidence and may support the stock price in the near term.
Earnings beat and strong China momentum could lift the stock, but high short interest and one‑time baseline adjustments add risk.
Executive hire could boost confidence in product rollout and market share gains.
AlphAI scores every news story that mentions STAA with an AI model for sentiment and relevance, and aggregates insider trades from STAAR SURGICAL CO's SEC EDGAR Form 4 filings. Figures refresh continuously.
STAAR Surgical (STAA) announced a $50M share repurchase program over 12 months, funded by free cash flow and cash on hand. The company has 50.1M shares outstanding as of August 2026. Analysts project revenues of $400M and earnings of $36.5M by 2029, assuming 11.3% yearly revenue growth. The buyback plan indicates management's focus on capital allocation amid demand and cost pressures in key markets like China.
2 min readSTAAR Surgical appointed David Bailey, former CEO, as Chief Commercial Officer to lead EVO ICL business. Bailey previously grew international revenue to 74% and ICL revenue to $32 million. He will focus on expanding in Asia, South America, and Africa.
2 min readSTAAR Surgical (NASDAQ:STAA) shares rose 2% after-hours after announcing a $50M share repurchase program. The medical device company plans to buy back shares over the next year, subject to market conditions. The authorization reflects confidence in its business and financial strength, according to the company.
1 min readSTAAR Surgical (STAA) reported Q2 2026 net sales of $93.5M, up 111% YoY, with net income of $8.1M. China sales more than doubled to $52.3M, now over half of total revenue. CEO Warren Foust outlined plans for growth. Global sales rose 6% excluding China, and gross margin improved to 74.5%. The company ended the quarter with $181.5M in cash and no debt.
2 min readSTAAR SURGICAL CO (STAA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 September 8, 2026 STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer The architect of STAAR's global refractive transformation returns to lead STAAR's next commercial chapter as EVO ICL outpaces a declining laser refractive market LAKE FOREST, C
2 min readSTAAR Surgical (STAA) appointed David Bailey, former CEO, as Chief Commercial Officer to drive growth of its EVO ICL vision-lens product. Bailey previously led STAAR from 2001 to 2008 and oversaw significant commercial expansion. The company highlights EVO ICL's competitive advantages, including a proprietary biocompatible material and a growing market share amid declining laser refractive procedures.
1 min readSTAAR Surgical (STAA) reported Q2 2026 net sales of $93.5M, up 111% YoY, driven by China and Americas growth. Net income was $8.1M, or $0.16 per share, with adjusted EBITDA at $20.0M. Gross margin improved to 74.5%. Management highlighted EVO Plus success in China and U.S. market share gains, but noted risks from China tariffs and supply chain constraints.
3 min readSTAAR Surgical (STAA) shares fell about 8% after Q2 results and sentiment cooled. The company reported sales and EPS above analysts’ estimates but cited uneven refractive market conditions and ongoing tariff and currency headwinds, especially in Asia. Stifel cut its price target to $28 from $31 (Hold) due to concerns about China. Shares closed at $24.15.
4 min readSimply Wall St reports STAAR Surgical (STAA) returned to profitability in Q2 2026 under new CEO Warren Foust. The company posted $93.54M sales and $8.06M net income, versus a loss a year earlier. For H1 2026, sales rose to $187.06M and EPS turned profitable. The article cites 2029 targets of $400M revenue and $36.5M earnings.
4 min readSTAAR Surgical said EVO Plus adoption should support China revenue growth, with Q3 and Q4 expected to be sequentially softer than Q2. The company plans to shift all China-destined manufacturing to Switzerland by year-end to reduce tariff margin pressure. It also plans broader lens product expansion and new clinical studies. Shares last traded at $24.76.
4 min read
